However, similar to persistent viral infections, the functions of type I IFNs in cancer can change throughout disease course, and there is evidence that, in certain contexts, IFN might act as a barrier to efficacious checkpoint-blockade therapy [reviewed in (224)]. The gene discussed is IFNA1; the disease is cancer.